Business Description
Organon & Co
NAICS : 325412
SIC : 2834
30 Hudson Street, Floor 33, Jersey City, NJ, USA, 07302
Description
Organon & Co is a science-based global pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Geographically, it derives a majority of revenue from Europe and Canada.
Financial Strength
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.08 | |||||
Equity-to-Asset | -0.12 | |||||
Debt-to-Equity | -7.28 | |||||
Debt-to-EBITDA | 4.4 | |||||
Interest Coverage | 5.31 | |||||
Piotroski F-Score | N/A/9 | |||||
Altman Z-Score | 1.65 | |||||
Beneish M-Score | -2.96 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -13.7 | |||||
3-Year EBITDA Growth Rate | -23.3 | |||||
3-Year EPS without NRI Growth Rate | -14.5 | |||||
3-Year FCF Growth Rate | -18.2 | |||||
Future 3-5Y Total Revenue Growth Rate Industry Rank | -5.13 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 33.63 | |||||
9-Day RSI | 37.9 | |||||
14-Day RSI | 39.26 | |||||
6-1 Month Momentum % | 3.26 | |||||
12-1 Month Momentum % | 15.7 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.61 | |||||
Quick Ratio | 1.2 | |||||
Cash Ratio | 0.3 | |||||
Days Inventory | 141.97 | |||||
Days Sales Outstanding | 77.06 | |||||
Days Payable | 192.8 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 3.56 | |||||
Dividend Payout Ratio | 0.26 | |||||
Forward Dividend Yield % | 3.56 | |||||
5-Year Yield-on-Cost % | 3.56 | |||||
3-Year Average Share Buyback Ratio | -0.1 |
Profitability Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 63.05 | |||||
Operating Margin % | 29.6 | |||||
Net Margin % | 20.42 | |||||
ROA % | 12.23 | |||||
ROIC % | 21.68 | |||||
ROC (Joel Greenblatt) % | 116.3 | |||||
ROCE % | 23.66 | |||||
Years of Profitability over Past 10-Year | 4 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 6.18 | |||||
PE Ratio without NRI | 6.15 | |||||
PS Ratio | 1.26 | |||||
Price-to-Free-Cash-Flow | 14.18 | |||||
Price-to-Operating-Cash-Flow | 7.43 | |||||
EV-to-EBIT | 8.82 | |||||
EV-to-EBITDA | 7.92 | |||||
EV-to-Revenue | 2.57 | |||||
EV-to-FCF | 29.06 | |||||
Earnings Yield (Greenblatt) % | 11.34 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NYSE:OGN
Executives
EMBED
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 6,365 | ||
EPS (TTM) ($) | 5.1 | ||
Beta | 0 | ||
Volatility % | 43.99 | ||
14-Day RSI | 39.26 | ||
14-Day ATR ($) | 0.909811 | ||
20-Day SMA ($) | 32.12 | ||
12-1 Month Momentum % | 15.7 | ||
52-Week Range ($) | 28.5 - 39.475 | ||
Shares Outstanding (Mil) | 253.64 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Organon & Co Filings
Document | Form | Filing Date | ||
---|---|---|---|---|
No Filing Data |